> Details

Bellocchio, Francesco; Lonati, Caterina; Ion Titapiccolo, Jasmine; Nadal, Jennifer; Meiselbach, Heike; Schmid, Matthias; Baerthlein, Barbara; Tschulena, Ulrich; Schneider, Markus; Schultheiss, Ulla T.; Barbieri, Carlo; Moore, Christoph; Steppan, Sonja; Eckardt, Kai-Uwe; Stuard, Stefano; Neri, Luca

Validation of a Novel Predictive Algorithm for Kidney Failure in Patients Suffering from Chronic Kidney Disease: The Prognostic Reasoning System for Chronic Kidney Disease (PROGRES-CKD)

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Validation of a Novel Predictive Algorithm for Kidney Failure in Patients Suffering from Chronic Kidney Disease: The Prognostic Reasoning System for Chronic Kidney Disease (PROGRES-CKD)
  • Contributor: Bellocchio, Francesco; Lonati, Caterina; Ion Titapiccolo, Jasmine; Nadal, Jennifer; Meiselbach, Heike; Schmid, Matthias; Baerthlein, Barbara; Tschulena, Ulrich; Schneider, Markus; Schultheiss, Ulla T.; Barbieri, Carlo; Moore, Christoph; Steppan, Sonja; Eckardt, Kai-Uwe; Stuard, Stefano; Neri, Luca
  • Published: MDPI AG, 2021
  • Published in: International Journal of Environmental Research and Public Health, 18 (2021) 23, Seite 12649
  • Language: English
  • DOI: 10.3390/ijerph182312649
  • ISSN: 1660-4601
  • Origination:
  • Footnote:
  • Description: Current equation-based risk stratification algorithms for kidney failure (KF) may have limited applicability in real world settings, where missing information may impede their computation for a large share of patients, hampering one from taking full advantage of the wealth of information collected in electronic health records. To overcome such limitations, we trained and validated the Prognostic Reasoning System for Chronic Kidney Disease (PROGRES-CKD), a novel algorithm predicting end-stage kidney disease (ESKD). PROGRES-CKD is a naïve Bayes classifier predicting ESKD onset within 6 and 24 months in adult, stage 3-to-5 CKD patients. PROGRES-CKD trained on 17,775 CKD patients treated in the Fresenius Medical Care (FMC) NephroCare network. The algorithm was validated in a second independent FMC cohort (n = 6760) and in the German Chronic Kidney Disease (GCKD) study cohort (n = 4058). We contrasted PROGRES-CKD accuracy against the performance of the Kidney Failure Risk Equation (KFRE). Discrimination accuracy in the validation cohorts was excellent for both short-term (stage 4–5 CKD, FMC: AUC = 0.90, 95%CI 0.88–0.91; GCKD: AUC = 0.91, 95% CI 0.86–0.97) and long-term (stage 3–5 CKD, FMC: AUC = 0.85, 95%CI 0.83–0.88; GCKD: AUC = 0.85, 95%CI 0.83–0.88) forecasting horizons. The performance of PROGRES-CKD was non-inferior to KFRE for the 24-month horizon and proved more accurate for the 6-month horizon forecast in both validation cohorts. In the real world setting captured in the FMC validation cohort, PROGRES-CKD was computable for all patients, whereas KFRE could be computed for complete cases only (i.e., 30% and 16% of the cohort in 6- and 24-month horizons). PROGRES-CKD accurately predicts KF onset among CKD patients. Contrary to equation-based scores, PROGRES-CKD extends to patients with incomplete data and allows explicit assessment of prediction robustness in case of missing values. PROGRES-CKD may efficiently assist physicians’ prognostic reasoning in real-life applications.
  • Access State: Open Access